MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has issued 298,824 shares of common stock as part of its incentive plan, with total voting rights now standing at 104,395,574 shares. The company has also provided an update on its block listing return, indicating a remaining balance of 9,038,342 unallotted ordinary shares. MaxCyte focuses on cell engineering technologies aimed at advancing cell-based therapeutics and bioprocessing applications.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
